Faculty Profiles - NISHIDA, Yoshihiro

Papers - NISHIDA, Yoshihiro

Division display 361 - 380 of about 708 ／ All the affair displays >>

Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study. Reviewed

Senda J, Ito K, Kotake T, Kanamori M, Kishimoto H, Kadono I, Nakagawa-Senda H, Wakai K, Katsuno M, Nishida Y, Ishiguro N, Sobue G.

Nagoya J Med Sci. Vol. 81 ( 3 ) page： 359-373 2019.8

Frequent mutations of genes encoding vacuolar H+ -ATPase components in granular cell tumors. Reviewed

Sekimizu M, Yoshida A, Mitani S, Asano N, Hirata M, Kubo T, Yamazaki F, Sakamoto H, Kato M, Makise N, Mori T, Yamazaki N, Sekine S, Oda I, Watanabe SI, Hiraga H, Yonemoto T, Kawamoto T, Naka N, Funauchi Y, Nishida Y, Honoki K, Kawano H, Tsuchiya H, Kunisada T, Matsuda K, Inagaki K, Kawai A, Ichikawa H.

Genes Chromosomes Cancer. Vol. 58 ( 6 ) page： 373-380 2019.6

エリブリンを用いた進行期軟部肉腫の治療成績東海骨軟部腫瘍コンソーシアム共同研究 Reviewed

中村知樹, 筑紫聡, 淺沼邦洋, 片桐浩久, 生田国大, 永野昭仁, 小澤英史, 山田聡, 紫藤洋二, 石村大輔, 山田健志, 河南勝久, 須藤啓広, 西田佳弘

日本整形外科学会雑誌 Vol. 93 ( 6 ) page： S1390 - S1390 2019.6

Roles of hyaluronan in cardiovascular and nervous system disorders Reviewed Open Access

Ding Hong-yan, Xie Ya-nan, Dong Qiang, Kimata Koji, Nishida Yoshihiro, Ishiguro Naoki, Zhuo Li-sheng

JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B Vol. 20 ( 5 ) page： 428 - 436 2019.5

A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610. Reviewed

Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Kawai A, Nishida Y, Hosaka M, Iwamoto Y, Fukuda H, Ozaki T.

Jpn J Clin Oncol. Vol. 49 ( 4 ) page： 379-382 2019.4

Fusion surgery with instrumentation following carbon ion radiotherapy for primary lumbar tumors: A case series. Reviewed

Ando K, Kobayashi K, Machino M, Ota K, Morozumi M, Tanaka S, Imai R, Nishida Y, Ishiguro N, Imagama S.

J Clin Neurosci. Vol. 62 page： 264-268 2019.4

Successful treatment of a recurrent chest wall desmoid tumor with cyclooxygenase-2 inhibitors. Reviewed

Kaiho T, Nakajima T, Nishida Y, Yoshino I

J Thorac Cardiovasc Surg. Vol. 157 ( 3 ) page： e195-e197. 2019.3

Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol. Reviewed International journal Open Access

Takeuchi A, Nomura A, Yamamoto N, Hayashi K, Igarashi K, Tandai S, Kawai A, Matsumine A, Miwa S, Nishida Y, Nakamura T, Terauchi R, Hoshi M, Kunisada T, Endo M, Yoshimura K, Murayama T, Tsuchiya H

BMC Musculoskelet Disord. Vol. 20 ( 1 ) page： 68 - 68 2019.2

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: A tenosynovial giant cell tumor (TGCT) is a locally aggressive benign neoplasm arising from intra- or extra-articular tissue. Diffuse TGCT (D-TGCT) most commonly develops in the knee, followed by the hip, ankle, elbow, and shoulder. Surgical removal is the only effective treatment option for the patients. However, a local recurrence rate as high as 47% has been reported. Recently, we revealed that zaltoprofen, a nonsteroidal anti-inflammatory drug possessing the ability to activate peroxisome proliferator-activated receptor gamma (PPARγ), can inhibit the proliferation of TGCT stromal cells via PPARγ. PPARγ is a ligand-activated transcription factor that belongs to the nuclear hormone receptor superfamily. It plays an important role in the differentiation of adipocytes from precursor cells and exhibits antitumorigenic effects on certain malignancies. Therefore, we are conducting this investigator-initiated clinical trial to evaluate whether zaltoprofen is safe and effective for patients with D-TGCT or unresectable localized TGCT (L-TGCT). METHODS: This study is a randomized, placebo-controlled, double-blind, multicenter trial to evaluate the safety and efficacy of zaltoprofen for patients with D-TGCT or L-TGCT. For the treatment group, zaltoprofen 480 mg/day will be administered for 48 weeks; the placebo group will receive similar dosages without zaltoprofen. Twenty participants in each group are needed in this trial (40 participants total). The primary outcome is the progression-free rate at 48 weeks after treatment administration. "Progression" is defined as any serious events (1. Repetitive joint swelling due to hemorrhage, 2. Joint range of motion limitation, 3. Invasion of adjacent cartilage or bone, 4. Severe joint space narrowing, 5. Increase in tumor size) requiring surgical interventions. We hypothesize that the zaltoprofen group will have a higher progression-free rate compared to that of the placebo group at 48 weeks. DISCUSSION: This is the first study to evaluate the efficacy of zaltoprofen in patients with D-TGCT or unresectable L-TGCT. We believe that the results of this trial will validate a novel treatment option, zaltoprofen, to stabilize disease progression for TGCT patients. TRIAL REGISTRATION: University Hospital Medical Information Network (UMIN) Clinical Trials Registry ( UMIN000025901 ) registered on 4/01/2017.

DOI： 10.1186/s12891-019-2453-z

Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis?: a multi-institutional study. Reviewed

Koike H, Nishida Y, Kohno K, Shimoyama Y, Motoi T, Hamada S, Kawai A, Ogose A, Ozaki T, Kunisada T, Matsumoto Y, Matsunobu T, Ae K, Gokita T, Sakai T, Shimizu K, Ishiguro N.

Hum Pathol. Vol. 84 page： 155-163 2019.2

Takeuchi A, Nomura A, Yamamoto N, Hayashi K, Igarashi K, Tandai S, Kawai A, Matsumine A, Miwa S, Nishida Y, Nakamura T, Terauchi R, Hoshi M, Kunisada T, Endo M, Yoshimura K, Murayama T, Tsuchiya H.

BMC Musculoskelet Disord. Vol. 20 ( 1 ) page： 68 2019.2

Wave Change of Intraoperative Transcranial Motor-Evoked Potentials During Corrective Fusion for Syndromic and Neuromuscular Scoliosis. Reviewed

Ando K, Kobayashi K, Ito K, Tsushima M, Morozumi M, Tanaka S, Machino M, Ota K, Nishida Y, Ishiguro N, Imagama S.

Oper Neurosurg (Hagerstown). Vol. 16 ( 10 ) page： 53-58 2019.1

Clinical Benefit of Preoperative Exercise and Nutritional Therapy for Patients Undergoing Hepato-Pancreato-Biliary Surgeries for Malignancy. Reviewed

Nakajima H, Yokoyama Y, Inoue T, Nagaya M, Mizuno Y, Kadono I, Nishiwaki K, Nishida Y, Nagino M

Ann Surg Oncol. Vol. 26 ( 10 ) page： 264-272 2019.1

RareとCommon：面白いのは何か？

西田佳弘

整形・災害外科 Vol. 62 ( 1 ) page： 1 2019.1

RareとCommon：面白いのは何か？

西田佳弘

整形・災害外科 Vol. 62 ( 1 ) page： 1 2019.1

Post-operative regression of retro-odontoid pseudotumors treated with and without fusion. Reviewed

Kobayashi K, Imagama S, Ando K, Nishida Y, Ishiguro N.

Eur Spine J. Vol. 27 ( 12 ) page： 3105-3112 2018.12

画像診断と病理骨芽細胞腫

駒田智大, 岩野信吾, 長縄慎二, 新井英介, 西田佳弘, 下山芳江

画像診断 Vol. 39 ( 1 ) page： 4-5 2018.12

【骨軟部腫瘍】AYA世代における骨軟部肉腫診療

西田佳弘

Clinician クリニシアン Vol. 65 ( 669 ) page： 1041-1047 2018.12

Feasibility and effects of a self-assembling peptide as a scaffold in bone healing: An in vivo study in rabbit lumbar posterolateral fusion and tibial intramedullary models. Reviewed

Ando K, Imagama S, Kobayashi K, Ito K, Tsushima M, Morozumi M, Tanaka S, Machino M, Ota K, Nishida K, Nishida Y, Ishiguro N.

J Orthop Res. Vol. 36 ( 12 ) page： 3285-3293 2018.12

Postoperative Complications Associated With Spine Surgery in Patients Older Than 90 Years: A Multicenter Retrospective Study. Reviewed

Kobayashi K, Imagama S, Sato K, Kato F, Kanemura T, Yoshihara H, Sakai Y, Shinjo R, Hachiya Y, Osawa Y, Matsubara Y, Ando K, Nishida Y, Ishiguro N.

Global Spine J. Vol. 8 ( 8 ) page： 887-891 2018.12

画像診断と病理骨芽細胞腫

駒田智大, 岩野信吾, 長縄慎二, 新井英介, 西田佳弘, 下山芳江

画像診断 Vol. 39 ( 1 ) page： 4-5 2018.12

　 PREV - NEXT 　

<NISHIDA, Yoshihiro>

Papers - NISHIDA, Yoshihiro